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Variation in fluoroquinolone 
pharmacodynamic parameter 
values among isolates of two 
bacterial pathogens of bovine 
respiratory disease
Xuesong Wen1, Ronette Gehring1, Jim E. Riviere1, Brian V. Lubbers2, Tara Nath Gaire2, 
Bre’Anna Wyche2, Breanna Fox2, Victoria Quichocho2 & Victoriya V. Volkova2
To design an antimicrobial treatment regimen for a bacterial disease, data on the drug 
pharmacodynamics (PD) against selected drug-susceptible strains of the pathogen are used. The 
regimen is applied across such strains in the field, assuming the PD parameter values remain the same. 
We used time-kill experiments and PD modeling to investigate the fluoroquinolone enrofloxacin PD 
against different isolates of two bovine respiratory disease pathogens: four Mannheimia haemolytica 
and three Pasteurella multocida isolates. The models were fitted as mixed-effects non-linear regression; 
the fixed-effects PD parameter values were estimated after accounting for random variation among 
experimental replicates. There was both inter- and intra- bacterial species variability in the PD 
parameters Hill-coefficient and Emax (maximal decline of bacterial growth rate), with more variable PD 
responses among M. haemolytica than among P. multocida isolates. Moreover, the Hill-coefficient was 
correlated to the isolate’s maximal population growth rate in the absence of antimicrobial exposure 
(a.k.a. specific growth rate; Spearman’s ρ = 0.98, p-value = 0.003, n = 6 isolates excluding one outlier). 
Thus, the strain’s properties such as growth potential may impact its PD responses. This variability can 
have clinical implications. Modifying the treatment regimen depending on phenotypic properties of the 
pathogen strain causing disease may be a precision medicine approach.
Effective antimicrobial treatment regimens for bacterial diseases are critical for achieving therapeutic success. 
Treatment regimens (i.e. the drug dose, dosing interval, and duration) are typically designed considering the anti-
microbial pharmacokinetics (PK) and the antimicrobial pharmacodynamics (PD) against the pathogen causing 
the disease1. The pharmacodynamics can be described by multi-parametric mathematical models, such as the 
maximum effect (Emax) model based on the Hill function2,3. Such models capture the relationship between the 
antimicrobial drug concentration and its effect on the growth rate of the exposed pathogen population2,3. These 
models can then be linked with those of the in vivo drug PK in the host to predict microbiological efficacy of the 
treatment regimen4–6. The regimen may be chosen based on the antimicrobial’s PK and PD characteristics for the 
bacterial pathogens most often involved in the disease etiology for those diseases often caused by multiple path-
ogens. The antimicrobial’s PD against each specific pathogen is described using in vitro, ex vivo, or in vivo studies 
conducted with selected drug-susceptible strains of the pathogen; the strains are judged as susceptible based on 
the antimicrobial’s minimum inhibitory concentration, MIC, for the strains. Then, the chosen regimen is applied 
across the infections by drug-susceptible strains in the field. It is assumed that values of the other PD parameters 
(e.g. the Hill-coefficient and Emax) remain the same across the strains classified as drug-susceptible based on the 
MIC, are independent of other strain properties, and do not to change during the treatment.
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We consider bovine respiratory disease (BRD) as an example of a multi-pathogen disease, where Mannheimia 
haemolytica and Pasteurella multocida are bacterial pathogens most often involved in the etiology7,8. A fluoro-
quinolone, enrofloxacin, is approved by the U.S. Food and Drug Administration with a single regimen for the 
treatment of BRD associated with either of these two respiratory pathogens9. Differences in the PD of the fluoro-
quinolone marbofloxacin between the drug-susceptible based on the MIC M. haemolytica and P. multocida have 
been reported in recent studies10,11. Specifically, the value of the PD parameter Hill-coefficient (H, which reflects 
how sensitive the bacterial population growth rate is to an increase in the antimicrobial concentration during the 
initial dynamic phase of the population-antimicrobial interactions) was observed to be higher for M. haemolytica 
than for P. multocida10. The value of the parameter reflecting the maximum effect on the bacterial population 
growth rate (Emax) was observed to be lower for M. haemolytica than for P. multocida10. However, only one iso-
late of each of the two pathogens was investigated in that study. Other authors considered as a PD outcome the 
absolute difference between the initial bacterial population size and the persister subpopulation remaining after 
24 hours of the antimicrobial exposure. That outcome was also different between M. haemolytica and P. multocida 
exposed to the fluoroquinolone marbofloxacin11, while intra-species differences among strains for this outcome 
were limited11. Differences in the PD responses inter- and intra- bacterial species can impact on which treatment 
regimen by the antimicrobial can achieve therapeutic success.
The goal of the present study was to investigate whether the reported differences in fluoroquinolone PD 
between M. haemolytica and P. multocida are solely a function of the bacterial species, or possibly a function of 
individual bacterial strains. We used the strains that would not be classified as fluoroquinolone-resistant based 
on the antimicrobial’s MIC. This is clinically important, for if the antimicrobial’s PD profile varies among the 
drug-susceptible strains within a specific species, than individualized treatment regimens (which may not be 
reflected in the current drug label) may need to be considered for effective therapy. This targeted hypothesis could 
be investigated by comparing the PD parameter values intra- and inter- the two bacterial species during the initial 
dynamics of the bacterial population growth/decline when exposed to various concentrations of the antimicro-
bial. This basic-science rooted approach considers the initial dynamics as its own outcome (i.e., apart from the 
size of the persister bacterial subpopulation after a 20 + hour exposure to the antimicrobial)3,6,12–15. We compared 
the initial in vitro PD of the fluoroquinolone enrofloxacin for several isolates of M. haemolytica and P. multocida, 
by comparing the parameter values of the Emax model for the isolates.
Results
Intra- and inter- bacterial species variation in fluoroquinolone pharmacodynamics. Time-kill 
experiments were conducted with enrofloxacin for each of four M. haemolytica isolates and three P. multocida iso-
lates (no further isolates of P. multocida were studied because a relatively low variation in enrofloxacin PD parameter 
values was observed among the isolates of this pathogen, as is detailed below). The data from the time-kill experi-
ments for M. haemolytica isolates are plotted in Fig. 1a–d and for P. multocida isolates in Fig. 2a–c. (The data for the 
Figure 1. Data from time-kill experiments with the fluoroquinolone enrofloxacin for four isolates of 
Mannheimia haemolytica from bovine respiratory disease cases. For each isolate and enrofloxacin concentration 
combination, the average result of at least two replicates of the experiment is plotted. (The isolate number 
corresponds to that in Table 1).
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P. multocida isolate - 1 have been also presented earlier12). For each isolate, the Emax model (Eq. 1) was fitted to the 
time-kill data for the initial dynamics of the bacterial population growth/decline when exposed to the antimicrobial 
(the linear phase of the bacterial population increase or decline). The model (Eq. 1) was fitted as a mixed-effect 
non-linear regression model, with the time-kill experiment date added as the random effect to account for random 
variability in the experimental conditions between the days (i.e., between the experiment replicates).
= −
×
+
E C E E C
EC C
( )
(1)
H
H H0
max
50
where:
 E C( )- bacterial population growth rate when exposed to the antimicrobial concentration C (log10(colony 
forming units (CFU/mL)))
C- antimicrobial concentration (μg/mL)
E0- bacterial population growth rate in the absence of antimicrobial exposure (log10(CFU/mL))
Figure 2. Data from time-kill experiments with the fluoroquinolone enrofloxacin for three isolates of 
Pasteurella multocida from bovine respiratory disease cases. For each isolate and enrofloxacin concentration 
combination, the average result of at least two replicates of the experiment is plotted. (The isolate number 
corresponds to that in Table 1).
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 EC50- concentration of the antimicrobial that achieves a 50% of the maximal decline in the bacterial popula-
tion growth rate (μg/mL)
 Emax- maximal decline of the bacterial population growth rate when exposed to the antimicrobial 
(dimensionless)
 H- Hill-coefficient reflecting steepness of the relationship between an increase in the antimicrobial concentra-
tion and an increase in the decline of the bacterial population growth rate (dimensionless).
The isolates of M. haemolytica varied in the sensitivity of the population growth/decline rate to an increase 
in enrofloxacin concentration. For two of the M. haemolytica isolates, the sensitivity was relatively low, with a 
relatively small increase in the population decline with an increase in enrofloxacin concentration (Fig. 1a,b). For 
the other two M. haemolytica isolates, the sensitivity was high, with a large increase in the population decline 
with an increase in enrofloxacin concentration (Fig. 1c,d). The pharmacodynamics were more variable among M. 
haemolytica isolates than among P. multocida isolates (Fig. 1 vs. Fig. 2). Also, the PD for P. multocida isolates were 
more similar to the first group of M. haemolytica isolates with a relatively low sensitivity of the population growth/
decline rate to an increase in enrofloxacin concentration (Figs 1a,b and 2).
The parameter values of the best-fit Emax model for enrofloxacin PD for each of the seven isolates are given 
in Table 1. Using these estimated Emax model parameter values, the population growth/decline of each isolate at 
different enrofloxacin concentrations was projected. These generalized projections were plotted together and 
this further visualized that the PD responses were more variable among M. haemolytica than among P. multo-
cida isolates (Fig. 3). There were also apparent inter-species differences, beyond the intra-species between-isolate 
variation; the maximal population decline tended to be greater for M. haemolytica than for P. multocida (Fig. 3).
Potential relationships between the bacterial isolate growth rate and fluoroquinolone phar-
macodynamics against the isolate. The results of the time-kill experiments and PD modeling suggested 
that the PD responses may depend on properties of the individual isolate within the pathogenic bacterial species. 
With the aim to identify the predictive properties, we analyzed relationships among the parameter values in the 
Emax model across the seven isolates studied. This analysis showed the isolate’s maximal population growth rate in 
the absence of antimicrobial exposure (a.k.a. specific growth rate) may be one of the properties impacting on the 
Bacterial species-
isolate
MIC (µg/mL) of 
enrofloxacin PD parameter
Parameter value estimate 
(95% CI of the estimate)
CV (%) of 
the estimate
M. haemolytica-1 0.01 E0, log(CFU/mL) × hour−1 0.25 (0.06, 0.43) 34
Emax 1.46 (0.87, 2.05) 19
EC50, µg/mL 0.03 (0.01, 0.05) 35
H 0.43 (0.12, 0.74) 33
M. haemolytica-2 0.05 E0, log(CFU/mL) × hour−1 0.26 (0.20, 0.32) 11
Emax 3.45 (1.68, 5.23) 24
EC50, µg/mL 0.75 (0.24, 1.26) 31
H 0.53 (0.38, 0.68) 13
M. haemolytica-3 0.04 E0, log(CFU/mL) × hour−1 0.49 (0.46, 0.51) 2
Emax 1.43 (1.20, 1.67) 8
EC50, µg/mL 0.03 (0.025, 0.03) 3
H 4.21 (2.84, 5.59) 15
M. haemolytica-4 0.50 E0, log(CFU/mL) × hour−1 0.37 (0.29, 0.45) 10
Emax 1.68 (1.10, 2.25) 16
EC50, µg/mL 0.69 (0.28, 1.11) 28
H 2.58 (0.35, 4.81) 40
P. multocida-1 0.01 E0, log(CFU/mL) × hour−1 0.32 (0.26, 0.38) 9
Emax 1.64 (1.34, 1.93) 8
EC50, µg/mL 0.11 (0.08, 0.13) 11
H 0.97 (0.73, 1.22) 12
P. multocida-2 0.02 E0, log(CFU/mL) × hour−1 0.50 (0.47, 0.53) 3
Emax 2.53 (2.19, 2.87) 6
EC50, µg/mL 0.14 (0.07, 0.20) 21
H 0.21 (0.04, 0.37) 37
P. multocida-3 0.01 E0, log(CFU/mL) × hour−1 0.25 (0.12, 0.38) 25
Emax 1.74 (1.44, 2.03) 8
EC50, µg/mL 0.25 (0.21, 0.28) 7
H 0.19 (0.06, 0.32) 33
Table 1. Parameter values of the sigmoid Emax pharmacodynamic (PD) models for the fluoroquinolone 
enrofloxacin for four isolates of Mannheimia haemolytica and three isolates of Pasteurella multocida from 
bovine respiratory disease cases.
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PD responses. With the exception of one outlier isolate, the H value increased with a higher maximal population 
growth rate E0 of the isolate across the M. haemolytica and P. multocida isolates studied (Fig. 4) (Spearman corre-
lation coefficient 0.98, p-value = 0.003, n = 6 isolates). No systematic relationship between the E0 value and Emax 
value was observed (Fig. 4) (Spearman correlation coefficient p-value = 0.905, n = 7 isolates).
No systematic relationship was observed between the isolate’s E0 or PD responses and its susceptibility to enro-
floxacin as measured by the MIC (p-value ≥0.150 for the Spearman correlation coefficient between the MIC and 
the value of either E0, H, Emax or E50; n = 7 isolates). However, the MIC value range was limited by design, because 
primarily isolates susceptible to enrofloxacin were included in the study (Table 1).
Discussion
This study was aimed at investigated a targeted hypothesis whether differences reported for the fluoroquinolone 
PD against two bacterial species commonly involved in a multi-pathogen respiratory disease are solely a function 
of the species, or possibly also a function of individual bacterial strains intra-species. Bacterial isolates that would 
not be classified as fluoroquinolone-resistant based on the antimicrobial’s MIC were considered. Isolates of the res-
piratory pathogen M. haemolytica varied in their PD responses to different concentrations of the fluoroquinolone 
enrofloxacin; the time-kill experimental data are given in Fig. 1 and the generalized PD projections in Fig. 3. The 
estimated Emax model parameter values used for the projections are given in Table 1. Two of the M. haemolytica iso-
lates (isolates 1 and 2 in Table 1 and Fig. 1a,b) demonstrated a sharply S-shaped curve of the relationship between 
an increase in the bacterial population decline with an increase in the drug concentration at <4x (isolate MIC), 
with no further increase in the population decline at the drug concentrations ≥4x (isolate MIC) (Fig. 3). This rela-
tionship was similar to that reported for M. haemolytica in an earlier study comparing PD of the fluoroquinolone 
marbofloxacin against M. haemolytica and P. multocida10. For these M. haemolytica, the H values were 0.43 and 
0.53, while the Emax values were 1.46 and 3.45, respectively. The other two M. haemolytica isolates (isolates 3 and 4 
Figure 3. Projected rates of population growth/decline of three isolates of Pasteurella multocida and four 
isolates of Mannheimia haemolytica when exposed to different concentrations of the fluoroquinolone 
enrofloxacin. (The isolate number corresponds to that in Table 1).
Figure 4. Relationships between values of individual parameters of the sigmoid Emax pharmacodynamic model 
for the fluoroquinolone enrofloxacin for an isolate of Pasteurella multocida (n = 3 studied) or Mannheimia 
haemolytica (n = 4 studied). Solid black symbols denote the data-points for M. haemolytica and white with black 
edge symbols the data-points for P. multocida. E0- bacterial population growth rate in the absence of 
antimicrobial exposure. Emax- maximal decline of the bacterial population growth rate when exposed to the 
antimicrobial. H – Hill-coefficient reflecting steepness of the relationship between an increase in the 
antimicrobial concentration and an increase in the decline of the bacterial population growth rate. The arrow 
identifies the outlier isolate in terms of the hypothesized relationship of H increasing with a higher E0.
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in Table 1 and Fig. 1c,d) demonstrated a high sensitivity to an increase in the drug concentration, with a continuing 
increase in the bacterial population decline with an increase in the drug concentration even above 4x (isolate MIC) 
(Fig. 3). For these M. haemolytica, the H values were 4.21 and 2.58, while the Emax values were 1.43 and 1.68, respec-
tively. Isolates of the respiratory pathogen P. multocida were less variable in the pharmacodynamic responses to 
different concentrations of the fluoroquinolone enrofloxacin. This can be seen in the results of the time-kill exper-
iments in Fig. 2, and the generalized PD projections using the Emax model of the isolate population growth/decline 
dependency on the drug concentration in Fig. 3 (the model parameter value estimates used for the projections are 
given in Table 1). The magnitude of population decline of all P. multocida isolates continued to increase even at the 
drug concentrations above 4x (isolate MIC) (Fig. 3). The Emax value for P. multocida isolates ranged 1.64–2.53, while 
the H value showed a relatively greater variation with the range 0.19–0.97 (Table 1).
At the same time, an inter-species variability in the fluoroquinolone PD responses was observed for these two 
pathogens commonly involved in the etiology of one disease (BRD). The magnitude of the population decline 
of all four M. haemolytica isolates at enrofloxacin concentrations ≥4x (isolate MIC) was greater compared to 
all three P. multocida isolates (Fig. 3). These results agree with the earlier reports that investigated other isolates 
of these species and concluded inter-species differences in the fluoroquinolone PD for these respiratory patho-
gens10,11. It should be noted however that no significant difference in the maximal population decline (difference 
between the initial bacterial population size and the persister subpopulation remaining after 24 hours, CFU/mL), 
was observed between M. haemolytica and P. multocida isolates when exposed for 24 hours to the fluoroquinolone 
marbofloxacin in serum and other ex vivo body fluids16.
The results demonstrated a marked variation in the PD responses to the fluoroquinolone enrofloxacin among 
individual isolates of pathogenic bacterial species, M. haemolytica and P. multocida (Figs 1, 2 and 3). To investi-
gate which isolate properties may influence the responses, we analyzed the relationships between values of the PD 
parameters for an isolate (Fig. 4, the parameter values are given in Table 1). This analysis suggested that the PD 
responses during the antimicrobial exposure may depend on such properties of the isolate as the maximal pop-
ulation growth rate during the exponential phase in the absence of the exposure (a.k.a. isolate’s specific growth 
rate). For six of the M. haemolytica and P. multocida isolates studied (after the exclusion of one outlier isolate), an 
isolate with a greater maximal population growth rate E0 in the absence of antimicrobial exposure experienced 
a steeper increase in the population decline with an increase in enrofloxacin concentration during the exposure, 
as reflected in a greater H value (Fig. 4). No systematic relationship was observed between E0 and the achieved 
maximal decline of the population growth rate during the exposure, Emax (Fig. 4).
Translation of the study findings to in vivo conditions will be complicated by that the BRD pathogen popu-
lations in the animal will be exposed to both enrofloxacin and its antimicrobially-active metabolites17,18. Thus, 
future studies could be designed to characterize the combined PD effects of the parent drug and its metabolites 
on the mono- or multi-pathogen populations. Also, the antimicrobial’s MIC for a given bacterial strain depends 
on the starting bacterial concentration for which the MIC is measured15,19. Values of the other PD parameters 
may be also changing depending on the bacterial concentration at the start and during the treatment. This may 
lead to yet unknown differences in the fluoroquinolone PD due to a different pathogen density between animals 
depending on the stage of the infectious disease (e.g., between therapeutically-treated animals with acute BRD vs. 
metaphylactically-treated animals in which the infection has not yet caused clinical BRD). To our knowledge, only 
data on the M. haemolytica density at the site of infection during acute BRD are available20. In this study, the starting 
bacterial density in the time-kill experiments was monitored to avoid the possible inoculum effect (Figs 1 and 2). 
Interested readers could pursue literature on investigations of potential role of the inoculum effect for fluoro-
quinolone treatment efficacy in vivo (see for example10,21).
Our study is limited to investigating the initial dynamic phase of the interactions between the antimicrobial 
and bacterial population; we consider this as a separate outcome from the size of the persister bacterial subpop-
ulation remaining after 20+ hours of the antimicrobial exposure3,6,12–15. For the studied pathogens, our12 and 
others11 earlier data showed this initial dynamic phase is limited to the first 8 hours in the time-kill experiments.
Another limitation of this study is that field isolates of P. multocida and M. haemolytica (from samples submit-
ted to the Kansas State Veterinary Diagnostic Laboratory) were used. The isolates were selected to provide temporal 
and geographical diversity, with no isolates originating from the same source premise (farm), and thus the isolates 
were assumed to be unrelated. However, the extent of circulation of individual P. multocida and M. haemolytica 
strains within a geographical area is not known. This imposes a risk that the studied isolates demonstrating similar 
PD responses and interpreted as unrelated isolates may have originated from a common ancestral strain.
In conclusion, the results of this in vitro study demonstrated a marked inter- and intra- bacterial species var-
iation in the PD responses to the fluoroquinolone enrofloxacin for pathogenic bacterial species, M. haemolytica 
and P. multocida. These pathogens are often involved in the complex etiology of a multi-pathogen respiratory 
disease – BRD. The pharmacodynamic differences of these magnitude, if confirmed by in vivo investigations, may 
require a targeted dosage regimen for different strains of the pathogens5. This study contributes to the developing 
body of literature investigating the potential variation in the antimicrobial PD against bacterial pathogen isolates 
for which the drug MICs are similar10,11,16. Modifications of the antimicrobial treatment regimen depending on 
the phenotypic properties of the pathogen strain causing disease – e.g., its PD responses and growth rate – may 
be an approach for precision medicine. The types of the modifications needed will require further investigation.
Material and Methods
Bacterial isolates. Four isolates of M. haemolytica and three isolates of P. multocida were obtained from the lungs 
of cattle affected with BRD under field conditions (the samples were routine submissions to the Kansas State Veterinary 
Diagnostic Laboratory during 2015–2016). All the isolates of P. multocida had typical colony morphology (greyish, 
spherical, and viscous colonies) on tryptic soy agar supplemented with 5% sheep blood (BAP, RemelTM, Lenexa, KS, 
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USA). All the isolates of M. haemolytica had typical colony morphology (greyish, spherical, and smooth colonies) on 
BAP. The species differentiation was confirmed using the indole test and MALDI-TOF mass spectrometry. The bacteria 
were stored in tryptic soy broth (RemelTM, Lenexa, KS, USA) supplemented with 15% glycerol at −80 °C.
MIC estimation. The minimum inhibitory concentration (MIC) of enrofloxacin for each isolate was 
first determined by the broth microdilution assay following the standard procedures22 in cation-adjusted 
Mueller-Hinton broth (MHB, RemelTM), aerobically, with an inoculum bacterial concentration of ~5 × 105 col-
ony forming units (CFU)/mL23. Enrofloxacin was purchased from Sigma-Aldrich, Inc (St. Louis, MO, USA). The 
quality control strains used in the microdilution assay were Escherichia coli ATCC® 25922™ and Staphylococcus 
aureus subsp. aureus ATCC® 29213™24. The microdilution assay following the standard procedures is based 
on serial two-fold dilution of the tested antimicrobial concentration22; thus, the assay only identifies the 
double-dilution interval in which the MIC value lies25. Because of this, the enrofloxacin MIC estimation for the 
isolate was further refined by the E-test® performed in accordance with the manufacturer’s recommendations 
(bioMérieux, Marcy-l'Étoile, France).
Time-kill experiments. Time-kill experiments with enrofloxacin were conducted with each of the seven bac-
terial isolates, using previously described procedures10,12,22. Specifically, for each isolate, an aliquot of the frozen 
stock was plated on BAP and incubated aerobically at 37 °C. From the overnight plate, several bacterial colonies 
were inoculated into brain heart infusion broth (BHI, RemelTM), which was incubated aerobically at 37 °C with 
shaking (200 rpm) overnight. The overnight culture was diluted 1:200 into fresh BHI and incubated at 37 °C for 
30 minutes - at which time the bacterial population was growing exponentially - and then diluted 1:20 into each of 
the individual flasks containing fresh BHI with different concentrations of enrofloxacin (0.5, 0.75, 1, 2, 3, 5, or 10 fold 
the MIC of the isolate) and into a control flask with fresh BHI (no enrofloxacin added). The starting bacterial con-
centrations are plotted in Figs 1 and 2. (Note that a fluoroquinolone MIC for a P. multocida or M. haemolytica isolate 
remains the same between MHB and BHI10; BHI is used for the time-kill experiments10,12). The drug-free control 
and drug-exposure cultures were incubated aerobically with shaking (200 rpm) at 37 °C, and sampled at 0, 1, 2, 3, 4, 
5, 6, 7, and 8 hour of the incubation. Previous studies in our laboratory with these bacterial species and enrofloxacin 
have showed that the initial linear phase of the bacterial population growth/decline is completed within 8 hours 
of the experiment12 (this is also similar to the action of the fluoroquinolone marbofloxacin against these bacterial 
species11). Thus, the Emax model can be fitted to the data from this initial experimental phase12. Each sample of the 
cultures underwent 10-fold serial dilutions in a 0.9% sterile saline solution, and two of the dilutions – chosen based 
on the expected bacterial concentration – were direct plated on BAP. These plates were incubated aerobically at 37 °C 
for 24 hours, at which time the colony counts were determined. The counts from the two dilutions of the sample were 
averaged providing an estimate of the bacterial concentration in the culture (CFU/mL) at the time point.
For each isolate, a time-kill experiment on a given date was performed including the isolate’s control cul-
ture (no enrofloxacin added) and its cultures with several of the enrofloxacin concentrations. Five to eight such 
time-kills experiments were performed with each isolate. This allowed producing the replicates of time-kill data 
for the isolate for each drug concentration (that is, each concentration 0.5, 0.75, 1, 2, 3, 5, or 10 fold the MIC was 
tested against the isolate in at least two independent experiments performed on different days), as well as suffi-
cient data for fitting the PD model with acceptable precision of the parameter estimates (see below).
Pharmacodynamic modeling. For each individual time-kill experiment with the isolate on a given date, for 
each drug concentration or the control, the determined log10-transformed bacterial concentration (log10(CFU/mL)) 
was plotted vs. time (i.e. on the semi-logarithmic scale). A linear regression model was fitted to the data and the 
slope provided an estimate of the rate of growth/decline of the bacterial population at that drug concentration or 
in the control. The growth/decline rate estimates across all drug concentrations and experiments for that isolate 
were pooled into a new dataset, keeping track of the experiment date. The sigmoid Emax model (Eq. 1) was fitted 
to the pooled dataset to describe the relationship between the drug concentration and the rate of growth/decline 
of the bacterial population. For each isolate, the model was fitted to the pooled dataset as a nonlinear mixed-effect 
regression model using the maximum likelihood method in the Phoenix® NLME software (Certara USA, Inc., 
Princeton, NJ, USA). The bacterial population growth/decline rate was the outcome, the antimicrobial drug con-
centration was the fixed effect, and the date of the experiment was the random effect in the model. The model’s 
goodness of fit to the data for the isolate was evaluated considering the Akaike’s Information Criterion (AIC); 
visual inspection of the plot of the predicted vs. observed rate of the bacterial population growth/decline at differ-
ent drug concentrations; and visual inspection of the residual diagnostic plots for outliers or trends which would 
suggest a poor model fit. Once the best-fit PD model form was determined, precision of estimation of the value of 
each parameter in the model was considered acceptable if the coefficient of variation was ≤ 40%. For each isolate, 
the time-kill data were amassed until the model parameters were estimated with that precision.
Availability of data and materials. The experimental data (results of the bacterial time-kill experiments) 
are included in Figs 1 and 2.
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